A ‘Scenic’ view on cancer treatment

Scenic Biotech awarded €3.1-million from Dutch government to progress CD47/QPCTL immuno-oncology program

Register for free to listen to this article
Listen with Speechify
AMSTERDAM, The Netherlands—Scenic Biotech BV, which describes itself as “a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses,” recently announced that it has been awarded a €3.1-million Innovation Credit from the Dutch government. The funds will be used to advance the company’s lead CD47/QPCTL immuno-oncology program through preclinical development toward human clinical studies.
Scenic’s CD47/QPCTL immuno-oncology program builds on seminal work by the Netherlands Cancer Institute (NKI) and Leiden University Medical Centre (LUMC). An enzyme present in cancer cells, QPTCL was first demonstrated as a promising target for immuno-oncology by using the Company’s proprietary high-resolution genetics platform called Cell-Seq. The results of this discovery were published in the journal Nature Medicine
“We are delighted to be selected for this award ... recognizing the potential of our program to develop a new cancer therapy. The funding will enable us to accelerate the optimization of our proprietary small molecule QPCTL inhibitors and then advance them towards filing an Investigational New Drug application with the U.S. Food and Drug Administration,” said Dr. Sebastian Nijman, co-founder and CEO of Scenic Biotech. “This is the first step in the drug review process before clinical trials can begin and will represent an exciting milestone for our company.”
After the IND approval phase, Scenic will seek a Partner to support human clinical trials.
QPCTL was found to be a druggable modifier of the CD47 innate immune checkpoint, which is one of the major mechanisms by which cancer cells evade detection by the immune system.  As a result of this activity, CD47 is also known as the “don’t eat me signal.”  After being the first to discover and validate QPCTL as a promising target in immuno-oncology, NKI and LUMCs scientists also showed that small molecule inhibitors of QPCTL can prevent the expression of functional CD47 on cancer cells, thereby causing the cancer cells to be attacked by macrophages and destroyed.
Scenic has gone on to develop a series of chemical inhibitors with potent inhibition against QPCTL and has filed a patent application related to this chemical series.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue